Literature DB >> 21193745

Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke.

Mohammad Al-Tamimi1, Elizabeth E Gardiner, Jim Y Thom, Yang Shen, Matthew N Cooper, Graeme J Hankey, Michael C Berndt, Ross I Baker, Robert K Andrews.   

Abstract

BACKGROUND AND
PURPOSE: Ischemic stroke induced by thrombosis may be triggered by atherosclerotic plaque rupture and collagen-induced platelet activation. Collagen induces glycoprotein VI shedding.
METHODS: We measured plasma-soluble glycoprotein VI (sGPVI) by enzyme-linked immunosorbent assay in 159 patients with acute (<7-day) ischemic stroke and age/sex-matched community-based control subjects.
RESULTS: sGPVI was elevated in stroke compared with controls (P=0.0168). ORs were higher in Quartile 4 for stroke cases (P=0.0121), and sGPVI was significantly elevated in stroke associated with large artery disease across Quartiles 2 to 4 and small artery disease in Quartile 4. sGPVI decreased 3 to 6 months after antiplatelet treatment, consistent with elevated sGPVI due to platelet activation during the thrombotic event. sGPVI correlated with P-selectin (P=0.0007) and was higher in individuals with the GPVIa haplotype (P=0.024).
CONCLUSIONS: Glycoprotein VI shedding is implicated in the pathology of acute ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21193745     DOI: 10.1161/STROKEAHA.110.602532

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  20 in total

Review 1.  Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment.

Authors:  Luis F Gonzalez-Cuyar; Joshua A Sonnen; Kathleen S Montine; C Dirk Keene; Thomas J Montine
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

2.  Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban.

Authors:  Takumi Aota; Katsuki Naitoh; Hideo Wada; Yoshiki Yamashita; Noriki Miyamoto; Masahiro Hasegawa; Hiroki Wakabayashi; Kakunoshin Yoshida; Kunihiro Asanuma; Takeshi Matsumoto; Kohshi Ohishi; Yuji Shimokariya; Norikazu Yamada; Masakatsu Nishikawa; Naoyuki Katayama; Atsumasa Uchida; Akihiro Sudo
Journal:  Int J Hematol       Date:  2014-09-25       Impact factor: 2.490

3.  Soluble GPVI is elevated in injured patients: shedding is mediated by fibrin activation of GPVI.

Authors:  Samantha J Montague; Céline Delierneux; Christelle Lecut; Nathalie Layios; Robert J Dinsdale; Christine S-M Lee; Natalie S Poulter; Robert K Andrews; Peter Hampson; Christopher M Wearn; Nathalie Maes; Jonathan Bishop; Amy Bamford; Chris Gardiner; Woei Ming Lee; Tariq Iqbal; Naiem Moiemen; Steve P Watson; Cécile Oury; Paul Harrison; Elizabeth E Gardiner
Journal:  Blood Adv       Date:  2018-02-13

Review 4.  Ischaemic stroke: a thrombo-inflammatory disease?

Authors:  Bernhard Nieswandt; Christoph Kleinschnitz; Guido Stoll
Journal:  J Physiol       Date:  2011-07-18       Impact factor: 5.182

Review 5.  [Acute ischemic stroke. New approaches to antithrombotic treatment].

Authors:  P Kraft; B Nieswandt; G Stoll; C Kleinschnitz
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

Review 6.  Functional significance of the platelet immune receptors GPVI and CLEC-2.

Authors:  Julie Rayes; Steve P Watson; Bernhard Nieswandt
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

Review 7.  Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'.

Authors:  Peter Kraft; Simon F De Meyer; Christoph Kleinschnitz
Journal:  J Cereb Blood Flow Metab       Date:  2012-07-18       Impact factor: 6.200

Review 8.  The Role of CLEC-2 and Its Ligands in Thromboinflammation.

Authors:  Danyang Meng; Man Luo; Beibei Liu
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

9.  The GPVI-Fc fusion protein Revacept improves cerebral infarct volume and functional outcome in stroke.

Authors:  Silvia Goebel; Zhongmin Li; Jasmin Vogelmann; Hans-Peter Holthoff; Heidrun Degen; Dirk M Hermann; Meinrad Gawaz; Martin Ungerer; Götz Münch
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

10.  SLAP/SLAP2 prevent excessive platelet (hem)ITAM signaling in thrombosis and ischemic stroke in mice.

Authors:  Deya Cherpokova; Markus Bender; Martina Morowski; Peter Kraft; Michael K Schuhmann; Sarah M Akbar; Cheryl S Sultan; Craig E Hughes; Christoph Kleinschnitz; Guido Stoll; Leonard L Dragone; Steve P Watson; Michael G Tomlinson; Bernhard Nieswandt
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.